Potential for Recurrent Monkeypox Outbreaks, Nirmatrelvir/Ritonavir Receiving FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19, Efficacy and Safety of Antimicrobial Stewardship Prospective Audit and Feedback in Patients Hospitalized with COVID-19 | VuMedi

MicrobeTV

Potential for Recurrent Monkeypox Outbreaks, Nirmatrelvir/Ritonavir Receiving FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19, Efficacy and Safety of Antimicrobial Stewardship Prospective Audit and Feedback in Patients Hospitalized with COVID-19

By MicrobeTV FEATURING Daniel Griffin, Vincent Racaniello

By MicrobeTV FEATURING Daniel Griffin, Vincent Racaniello

8 views

August 2, 2023

Comments 0

Login to view comments. Click here to Login